A possible theory that may explain this reduced efficacy of immunotherapy in NASH-related HCC claims that there are a lot of activated CD8+/PD1+ T-cells causing tissue damage and lacking immune surveillance functions [197]. Here, PDCD1 is linked to metabolic dysfunction-associated steatohepatitis.